<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Facilitating Drug Discovery with 3D In Vitro Oncology Models

derivation of 3d spheroid and organoid in vitro models from human patient tumors

derivation of 3d spheroid and organoid in vitro models from human patient tumors Around 95% of new anticancer drugs eventually fail in clinical trials, despite promising results when tested on 2D in vitro preclinical models. New models that better mimic tumor biology in vivo can facilitate more efficient and translatable drug discovery research.

This post looks at advanced 3D in vitro models, including tumor spheroids and organoids.

Why Aren’t 2D In Vitro Models More Translatable?

Currently, a high proportion of drug discovery is performed using cell cultures. This increases the speed and efficiency of preclinical oncology research, but only so far as those results translate into the clinical environment. Culturing cells on flat plasticware results in artificial 2D monolayering. Cells suffer additional stress as they spread and flatten on the plastic surface, and they don’t engage in efficient cell-cell and cell-matrix interactions.

All of these factors influence gene expression and protein function. In addition, cancer cell lines accumulate genetic aberrations with increasing passage numbers. Combined with positive clonal selection, which is highly sensitive to culture conditions, this leads to cell line heterogeneity.

This raises the question of whether 2D cell culture models represent the corresponding in situ tumor well enough. And if not, is this leading to poor in vivo translation.

Is there a better way to facilitate oncology drug discovery in vitro?

3D In Vitro Models Can Be More Effective

More recently, 3D cell cultures have been developed to more closely mimic in vivo heterogeneity, native histologic architecture, and response to therapeutics.

The term ‘3D cell culture’ refers to both spheroid and organoid 3D structures. Although the terminology has been used interchangeably, there are notable differences between these two techniques.

Tumor Spheroids

Tumor spheroids are spherical aggregates of tumor cells that are self-organizing and self-renewing. They may originate from single-cell suspensions of tumor cell lines, patient-derived tumor cells, or tumor stem cells cultured in nonadherent substrates.

One assay which makes great use of tumor spheroids is the 3D Tumor Growth Assays (3D TGA), a proven platform for oncology drug development. The 3D TGA provides tumor conditions which more closely represent the human condition than 2D culture.

Within the assay, tumor cells are embedded in a low-stiffness, laminin-rich extracellular matrix. Human mesenchymal stem cells and patient-derived Cancer-Associated Fibroblasts may also be included in the co-culture. This provides the paracrine signaling present in the tumor microenvironment (TME) of solid tumors.

The 3D TGA also has hormones added (e.g. DHT/E2), glucose restricted to ≤7mM, and an acidic pH of 6.8 maintained. This all provides a 3D assay that is “humanized” and TME-aligned for use in profiling PDX-derived cells and drug panels.

Studies have shown a correlation between response to anticancer agents in 3D TGA, in vivo models, and expected clinical outcome.

Tumor Organoids

Organoids are mini 3D versions of organs, grown in vitro. Tumor organoids, specifically, are three-dimensional models of primary tumor tissue obtained from fresh biopsies.

Organoids can be generated from either stem cells or primary tissue (harvested or biopsied). Stem cells can be either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) whose self-renewal and differentiation properties make it possible to generate organoids containing virtually any cell type.

Organoids are generated by mechanical or enzymatic digestion of the original tumor section into small pieces. Similarly to the 3D spheroid assays, cells are then embedded in a basement membrane matrix such as Matrigel™ or different type of collagen with a cocktail of signaling chemicals to drive the formation of the desired organoid identity.

Alternatively, stem cells can be differentiated into specific cell types, then implanted in a specific 3D environment after maturation.

What is an Organoid?

According to Lancaster and Knoblich, certain criteria need to be fulfilled to fit the definition of an organoid:

  • Multiple organ specific cell types: so, organoids must contain more than one cell type of the organ it models.

  • Organoids must be able to exhibit some organ specific functions (e.g. excretion, filtration, neural activity, contraction).

  • Cells should be organized similarly to the organ.

Organoids now represent a growing list of diverse organs. Lung, stomach, pancreas, brain, eye, liver, skin, and many more as well as neoplastic tissues have been generated. Numerous publications show that organoids recapitulate tumor heterogeneity – preserving the molecular features of the primary tumor, including genomic as well as transcriptomic alterations.

A recent study by Sachs et al derived 95 breast cancer organoids from 155 tumors. Gene expression analysis showed that the organoids display representative gene expression profiles of breast cancer subtypes. The organoid morphologies were also retained, and matched the histopathology, and hormone receptor and HER2 status of the original tumor.

This study illustrates the potential of organoid cancer models for drug development and translational medicine.

Organs-on-a-Chip

One of the hot topics in in vitro research is modelling human organs on a chip, physically and chemically mimicking the in vitro environment with microfluidic device technology.

In addition to mimicking the 3D structure of a tissue or organ, organs-on-a-chip more accurately represent physiological conditions and the structural microenvironment, providing more predictive in vitro assays.

Functions of various organs and tissues, such as the lung, liver, kidney, and gut, have been reproduced as in vitro models, and tumor-on-a-chip technology has been extensively published.

Summary

3D in vitro models, such as tumor spheroids and organoids, offer new opportunities for building and applying functional three-dimensional in vitro human tumor translational models for oncology research, immunotherapy studies, and drug screening.


Related Posts